COMA-F: The COMA Family Program: A Skills-Based Resiliency Program for Caregivers of Patients With Severe Acute Brain Injuries

Sponsor
Massachusetts General Hospital (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05761925
Collaborator
University of North Carolina, Chapel Hill (Other)
10
1
1
11.1
0.9

Study Details

Study Description

Brief Summary

The purpose of this study is to pilot a psychosocial skills-based intervention for caregivers of patients with severe acute brain injuries. The data we gather in this study will be used to further refine our COMA-F intervention.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: COMA-F
N/A

Detailed Description

The goal of this study is to refine our proposed intervention (COMA-F) through an open pilot. We will deliver an open pilot of the intervention (N=5 caregivers) to evaluate initial feasibility and acceptability using exit interviews and pre-post assessments.

The open pilot will take place at the Massachusetts General Hospital neurological intensive care unit (NICU) or step-down unit using our established methodology successfully implemented during our previous R21 of our Recovering Together study. Study clinicians will deliver 6, 30 minute sessions of the intervention (at bedside or on Zoom, depending on participant preference). All participants will complete measures at baseline, and after completion of program (6 weeks). They will also complete measures of emotional distress weekly. At the completion of the program, participants will engage in a 5-10 minute exit interview where they will provide feedback of the intervention.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
10 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Prevention
Official Title:
The COMA Family Program: A Skills-Based Resiliency Program for Caregivers of Patients With Severe Acute Brain Injuries (COMA-F)
Anticipated Study Start Date :
Feb 28, 2023
Anticipated Primary Completion Date :
Dec 1, 2023
Anticipated Study Completion Date :
Feb 1, 2024

Arms and Interventions

Arm Intervention/Treatment
Experimental: Intervention

Caregivers will participate in 6 30-minute skills sessions. A clinical psychologist will deliver all of the sessions. The main intervention goal is to provide dyads with resiliency skills to reduce emotional distress and prevent chronic distress.

Behavioral: COMA-F
The intervention will teach resiliency skills (mindfulness, coping, interpersonal communication, etc.) to the comatose patient's caregiver. These sessions will take place in person or on Zoom, depending on the participant's preference.

Outcome Measures

Primary Outcome Measures

  1. Preliminary feasibility of recruitment [0 weeks]

    We will assess the proportion of caregivers enrolled from the number of caregivers eligible.

  2. Preliminary feasibility of assessments [Change from pre-test (0 weeks) to post-test (6 weeks).]

    We will assess the proportion of caregivers enrolled that completed all assessments.

  3. Preliminary feasibility of adherence [Change from pre-test (0 weeks) to post-test (6 weeks).]

    We will assess the proportion of enrolled caregivers that complete 4 out of 6 sessions.

  4. Preliminary feasibility of therapist fidelity [Change from pre-test (0 weeks) to post-test (6 weeks).]

    We will assess the number of sessions in which the therapist adhered 100% to the treatment manual based on a fidelity checklist.

  5. Preliminary treatment satisfaction [post-test (6 weeks after session 1)]

    We will assess the proportion of enrolled caregivers that score above the midpoint on the Client Satisfaction Questionnaire-3. Scores range from 3 to 12; higher values indicate greater satisfaction.

  6. Preliminary treatment credibility [post-test (6 weeks after session 1)]

    We will use the Credibility and Expectancy Questionnaire (CEQ) to assesses caregivers perceptions that the treatment will work after learning about the study. Scores range from 3-27; higher ratings indicate more belief that the program is logical and will help with the intended outcome.

Other Outcome Measures

  1. Hospital Anxiety and Depression Scale (HADS) [Change from pre-test (0 weeks) to post-test (6 weeks)]

    We will use the Hospital Anxiety and Depression Scale HADS, a 14-item measure that assesses symptoms of emotional distress (anxiety and depression). The anxiety and depression sub-scale are each scored from 0-21, with higher scores indicating greater severity of symptoms. Scores can be summed to create a global emotional distress score (0-42).

  2. Posttraumatic Stress Disorder Checklist-5 [Change from pre-test (0 weeks) to post-test (6 weeks)]

    Post-Traumatic Stress Disorder Checklist - 5; range 0-80, higher scores indicate greater posttraumatic stress

  3. Cognitive and Affective Mindfulness Scale-Revised (CAMS-R) [Change from pre-test (0 weeks) to post-test (6 weeks)]

    Cognitive and Affective Mindfulness Scale-R (CAMS-R); 12-48, higher scores indicate greater perceived mindfulness

  4. Measure of Current Status Part A (MOCS-A) [Change from pre-test (0 weeks) to post-test (6 weeks)]

    Measure of Current Status Part A (MOCS-A); 0-52; higher scores indicate greater perceived ability to cope

  5. Toronto Mindfulness Scale-Trait (TMS-Trait) [Change from pre-test (0 weeks) to post-test (6 weeks)]

    Toronto Mindfulness Scale-Trait (TMS-Trait); 0-52, higher scores indicate greater perceived mindfulness (specifically curiosity and de-centering)

  6. Enhancing Recovery in Coronary Heart Disease Social Support Instrument (ESSI) [Change from pre-test (0 weeks) to post-test (6 weeks)]

    Enhancing Recovery in Coronary Heart Disease Social Support Instrument (ESSI); the ESSI measures the participant's range of social support in their life. Higher scores indicated higher levels of social support. Total scores range from 8 to 34.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:

Eligible caregivers must be caregivers of patients considered to have severe acute brain injury and be unable to communicate with their loved one or clinical team due to their incapacitated nature. Caregivers must meet the following inclusion criteria:

  1. Age 18 or older

  2. English-speaking

  3. Confirmed by the primary clinical team as the primary caregiver for a patient who:

  1. Is age 18 or older; b. Has been admitted to the ICU with a severe acute brain injury: i. Ischemic stroke ii. Intracerebral hemorrhage iii. Subarachnoid hemorrhage
  1. Traumatic brain injury v. Hypoxic-ischemic encephalopathy; c. In the judgment of the medical team, has had a Glasgow Coma Scale score below 9 while not intubated OR an inability to following meaningful commands while intubated at any point during his or her hospitalization course for greater than 24 consecutive hours, felt to be due to the brain injury itself and not a confounding factor (i.e., sedation, seizures, etc.);
  1. Is still alive in the ICU at the time that the clinical team approaches the primary caregiver about possible recruitment; e. Has a prognosis for survival of greater than 3 months and does not have a concurrent diagnosis of a terminal illness or injury, as judged by the clinical team.
Exclusion Criteria:

Patient has terminal diagnosis

Caregiver has:
  • Lack of access to internet and/or a device with a camera

  • Current untreated or unstable severe mental health conditions like bipolar disorder, schizophrenia, or active substance use

Contacts and Locations

Locations

Site City State Country Postal Code
1 Massachusetts General Hopsital Boston Massachusetts United States 02114

Sponsors and Collaborators

  • Massachusetts General Hospital
  • University of North Carolina, Chapel Hill

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Ana-Maria Vranceanu, PhD, Associate Professor/Director, Massachusetts General Hospital
ClinicalTrials.gov Identifier:
NCT05761925
Other Study ID Numbers:
  • 2021P000423
First Posted:
Mar 9, 2023
Last Update Posted:
Mar 9, 2023
Last Verified:
Feb 1, 2023
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Ana-Maria Vranceanu, PhD, Associate Professor/Director, Massachusetts General Hospital
Additional relevant MeSH terms:

Study Results

No Results Posted as of Mar 9, 2023